UNSPSC 51151551: Tacrine hydrochloride

This classification denotes an acetylcholinesterase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4966RNG0BU. European Medicines Agency schedules Tacrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04665MIG. Tacrine hydrochloride generally arises in the molecular formula C13H15CLN2. The term 'tacrine hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule tacrine hydrochloride under HS 29339990 and SITC 51577.

As of Q4 2014, TACRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tacrine hydrochloride bears US NLM identifiers UMLS ID C0699954 and NCI Concept Code C47742. SMILES: C1CCC2C(C1)C(C3C(N2)CCCC3)N.CL.

UNSPSC 51151551 Tacrine hydrochloride is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local procurement activity tagged to this code shows little relevance to the actual chemical product. The two recent opportunities on record—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs—address pharmaceutical procurement broadly rather than tacrine hydrochloride specifically. The mismatch suggests either inconsistent code assignment in the source data or that jurisdictions are using this code as a catch-all for pharmaceutical acquisitions outside their standard taxonomy mapping.

Activity under this code is sparse and geographically scattered. Seminole County posted an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023—though this date appears inconsistent with the posting date. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription contracting, signaling early-stage planning rather than a committed procurement. No dollar values, set-asides, or repeat buyers emerge from the record. Given the limited recent activity and the apparent disconnect between the code's nominal scope and what is actually being solicited, this code warrants monitoring for clarification rather than active pursuit at this time.